middle.news
Neurizon Secures $5.6M Tax Rebate to Accelerate ALS Drug NUZ-001
9:33am on Thursday 18th of September, 2025 AEST
•
Biotechnology
Read Story
Neurizon Secures $5.6M Tax Rebate to Accelerate ALS Drug NUZ-001
9:33am on Thursday 18th of September, 2025 AEST
Key Points
Advance and Overseas Finding awarded for NUZ-001 R&D expenditure 2025-2027
43.5% cash rebate on eligible Australian and overseas development costs
Rebate expected to total AUD 5.6 million for FY2025
Funding supports pre-clinical to clinical trial phases including HEALEY ALS Platform Trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE